Exagen Inc. (XGN)

NGM – Real vaqt narxi. Valyuta: USD

3.71

-0.27 (-6.78%)

Yopilishda: May 12, 2026, 4:00 PM EDT

28.04.2026

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago.

27.04.2026

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026.

10.03.2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

10.03.2026

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

10.03.2026

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

03.03.2026

Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: Investor meetings and fireside chat at 3:00 p.m.

24.02.2026

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).

Videolar

No Data

There is no data to display

Press-relizlar

10.03.2026

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

11.01.2026

Exagen Inc. Announces Select Preliminary 2025 Financial Results

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.

04.11.2025

Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.

23.10.2025

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois.

Exagen Inc. (XGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Exagen Inc. (XGN)

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Videolar

No Data

Press-relizlar

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Videolar

No Data

Press-relizlar

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Search stocks

Exagen Inc. (XGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Exagen Inc. (XGN)

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Videolar

No Data

Press-relizlar

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Videolar

No Data

Press-relizlar

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence